Sun Pharmaceutical Industries has introduced its innovative biologic therapy ILUMYA (Tildrakizumab) in India for the treatment of moderate-to-severe plaque psoriasis.

Widely recognised by dermatologists in the US and globally, ILUMYA has built a strong reputation as a safe and effective treatment option for chronic plaque psoriasis.

Commenting on the launch, Kirti Ganorkar, Managing Director of Sun Pharma, said ILUMYA will offer patients a reliable and advanced therapy to better manage their condition.